Sam Lockhart

Physician-Scientist using genetics to find new treatments for cardiometabolic disease

[Sam Lockhart @slockhart05]

🚨We're hiring!
Come join us in Belfast at @WWIEM_QUB 🔬
We're looking for a postdoc to help uncover the mechanism behind a novel genetic cause of heart failure, funded by @TheBHF.
Apply here👉 https://t.co/Itm4eafmlU
Questions? Reach out via X/LinkedIn/Email!
@ProfDavidGrieve

[Daniel J Drucker @DanielJDrucker]

MC3R has a conserved role across mammals in controlling growth and pubertal timing @MolMetab https://t.co/LCKDDmKkF1

[Marios Georgakis @MariosGeorgakis]

@drjohnm How would you interpret the genetic findings?

https://t.co/MtIg6A65Il

https://t.co/UHSYtpaNBe

[Ethan J. Weiss @ethanjweiss]

This is a really important point. Nobody is saying come off the diet. I myself have been low-carb/keto since 2018. What most of us are advocating is that for those people who are on these diets and find benefit and also have these increases in LDLc/ApoB, do not assume that it is safe from the perspective of ASCVD risk. Instead, most would advocate to either 1) make some modest changes to diet (add fiber, reduce SFA, slightly add back some carbs), or 2) add a medicine to reduce ApoB (ezetimibe, statins, PCKS9i or other).

Importantly, this does not mean that there is zero chance these increases in ApoB are safe(er) in the context of a low-carb diet. What it means is that given the extraordinary amount of evidence linking ApoB to ASCVD risk in all other contexts, the default assumption should be that this is no different in this context and that until and unless it is shown categorically in at least one well-powered clinical study looking at hard clinical outcomes, nobody should assume that this context is any different from any other context we have seen yet

[Marios Georgakis @MariosGeorgakis]

I lost the count of how many posts I saw about the Keto-CTA study the last days.

One issue that directly relates to the lack of association between ApoB/LDL-C and plaque progression that I haven't seen anyone talk about is collider bias👇

[Gemma.V.Brierley @GV_Brierley]

Interested in undertaking a PhD to contribute to the understanding of the links between insulin resistance and cardiovascular disease? Apply to join my lab at the RVC with this fully-funded PhD studentship.

[Derek A Mann @derekamann1]

Our latest paper, published today in FEBS Letters is a chemical biology study on development of drugs selectively targeting HDAC6 with demonstration of efficacy in a human model of liver fibrosis. Congratulations to all authors. https://t.co/KSDLWKkk9s

[Olivia Conway @olivia_j_conway]

Very excited to finally share our work using subcellular proteomics to look at insulin-stimulated protein movement in adipocytes! 🧵below: (1/5)

https://t.co/ziznyembiL

@DPhaz @IMS_MRL

[Daniel Fazakerley @DPhaz]

Please check out Liv's preprint and thread below!

[Ben Loughrey @DrBenBanner]

Delighted to see this published in @EJEndo after many years of work

Forever grateful to Prof Márta @KorbonitsL for giving me the chance to work on this

Reassessing the role of the p.(Arg304Gln) missense AIP variant in pituitary tumorigenesis https://t.co/XzSM2XdeKC

[Dr Rebecca Coll @Rebecca_Coll]

We are recruiting a student for a really exciting PhD project on understanding how high plasma suPAR predicts poor outcome in patients with ARDS @dfmcauley @QUBCritCareResp @WWIEM_QUB - any questions please get in touch! (open to UK and RoI)
https://t.co/60LQaBEkO7

[Inst Metabolic Science-Metabolic Research Labs @IMS_MRL]

For International Women’s Day, we are celebrating the women of the @IMS_MRL, the @MRC_Epid and GDAR Network.

Meet Professor Sue @ozannelab, Director of the IMS-MRL & Professor of Developmental Endocrinology

👉 https://t.co/T9xG6idm9l

#AccelerateAction #IWD2025

[stephen o'rahilly (its pronounced O-RA-hill-EEE) @StephenORahilly]

' https://t.co/FvGiYtQ2Jw via @people. Such a tragic story. Hopefully, thanks to recent science, we will have effective therapy. @IMS_MRL @DrFejzo @slockhart05

[Tune H. Pers @tunepers]

Thanks to the reviewers 🙏

Also, we’re looking for a Postdoc to explore how obesity-associated genetic variants impact hypothalamic circuits using CRISPR-based Perturb-seq & in vivo metabolic phenotyping

https://t.co/XoDCdpK5bJ

#neuroscience #obesity
3/3

[Gerard Walls @gwalls89]

Have you got a history of heart disease and/or cancer? Or are you the relative of someone who has?

Our CardioOncology research group is gathering the public's opinion on what our priorities should be!

✅ only takes 15mins
✅ completely confidential

https://t.co/vPD5yjSuWT

[Brian Lam @brianlamx]

Our latest effort in mapping the human hypothalamus:
https://t.co/zGtiZRrPkY
@IMS_MRL @MPI_Metabolism @gilesyeo @gkcdowsett @JohnTadross

[Charlotte Summers @charlot_summers]

Great to see this call for action about clinical academic career crisis.
https://t.co/5t6jRxXYPW

[stephen o'rahilly (its pronounced O-RA-hill-EEE) @StephenORahilly]

Agree that it’s great to see this. Delivering 2.3 will be key. I don’t doubt the funders desire to see this happen. I worry about the reality of commitment from NHS. Colleges and particularly HEE, which seems to be intent on stifling excellence and academic aspiration

[Veera Rajagopal  @doctorveera]

Association of polygenic scores for neuropsychiatric traits with self-reported professions based on analysis of 420k individuals from UK Biobank and Million Veteran Program. Look at the 'arts & design' category. Artistic talent comes at a cost--a piece of your mind :)

Voloudakis et al. Nat Hum Behav
https://t.co/99o4O12Tdk